Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
6
×
detroit blog main
detroit top stories
gene therapy
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
6
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
6
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
gilead sciences
merck
alzheimer's disease
deals
fda
nonalcoholic steatohepatitis
pfizer
startups
abbvie
bayer
cell therapy
What
bio
roundup
cancer
pfizer’s
amid
bombast
caught
companies
corner
coronavirus
debate
develop
discussion
drug
efforts
meso’s
miss
pandemic
presidential
promise
response
tuesday’s
vaccine
viewers
abbvie’s
acquisitions
ahead
albert
approval
arena’s
biggest
biofourmis
biogen’s
biopharmaceutical
bounty
bourla
bucks
celebrate
ceo
chance
Language
unset
unknown
Current search:
" raleigh-durham blog main "
×
" seattle blog main "
×
" gene therapy "
×
" cancer immunotherapy "
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More